Department of Medical Oncology, UCL Cancer Institute, University College London, London, UK.
Department of Medicine, King's College Hospital NHS Trust, London, UK.
Nat Rev Urol. 2021 Apr;18(4):185-187. doi: 10.1038/s41585-020-00419-z.
The COVID-19 pandemic has resulted in a substantial increase in waiting times for cystoscopies, prompting concerns of delayed diagnoses and substandard surveillance of bladder cancer. Expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this problem, and several novel biomarkers have shown promise for this purpose.
COVID-19 大流行导致膀胱镜检查的等待时间大幅延长，这引发了人们对膀胱癌诊断延误和监测标准下降的担忧。在诊断和监测途径中扩大尿生物标志物的作用可能是解决这一问题的策略，一些新的生物标志物已显示出在这方面的应用前景。
